Keryx Biopharm Inc (KERX) 4.15 $KERX
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE - Fri Sep 02, 10:45PM CDT
LOS ANGELES, CA / ACCESSWIRE / September 2, 2016 / Lundin Law PC (the "Firm"
announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (NASDAQ: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the "Class Period". Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline.
KERX: 4.15 (+0.02)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - KERX
ACCESSWIRE - Fri Sep 02, 7:00PM CDT
NEW YORK, NY / ACCESSWIRE / September 2, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company" (NASDAQ: KERX) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-06233, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Keryx securities between February 25, 2016 and July 29, 2016 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act".
KERX: 4.15 (+0.02)
Commit To Purchase Keryx Biopharmaceuticals At $3, Earn 26.7% Using Options
DividendChannel.com - Thu Sep 01, 10:47AM CDT
Investors considering a purchase of Keryx Biopharmaceuticals Inc. stock, but tentative about paying the going market price of $4.11/share, might benefit from considering selling puts among the alternative strategies at their disposal.
KERX: 4.15 (+0.02)
Keryx Biopharmaceuticals to Present at Two Upcoming Investor Healthcare Conferences
GlobeNewswire - Thu Sep 01, 7:30AM CDT
Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast management presentations at the following investor conferences:
KERX: 4.15 (+0.02)
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm
ACCESSWIRE - Wed Aug 31, 5:03PM CDT
IRVINE, CA / ACCESSWIRE / August 31, 2016 / Khang & Khang LLP (the "Firm" announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (Nasdaq: KERX). Investors who purchased or otherwise acquired shares between February 25, 2016 and August 1, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the October 3, 2016 lead plaintiff motion deadline.
KERX: 4.15 (+0.02)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. - KERX
GlobeNewswire - Wed Aug 31, 2:53PM CDT
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Keryx Biopharmaceuticals, Inc. securities (NASDAQ:KERX) from February 25, 2016 through August 1, 2016, both dates inclusive (the "Class Period". The lawsuit seeks to recover damages for Keryx Biopharmaceuticals investors under the federal securities laws.
KERX: 4.15 (+0.02)
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Keryx Biopharmaceuticals, Inc.
Marketwire Canada - Wed Aug 31, 2:29PM CDT
OKLAHOMA CITY, OK--(Marketwired - Aug 31, 2016) - On August 26, 2016, a class action lawsuit was filed in the United States District Court for the District of Massachusetts against Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is September 2, 2013 through August 1, 2016.
KERX: 4.15 (+0.02)
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE - Wed Aug 31, 10:27AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the "Firm" announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (Nasdaq: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the "Class Period". Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline.
KERX: 4.15 (+0.02)
Lawsuit for Investors in shares of Keryx Biopharmaceuticals (NASDAQ:KERX) announced by Shareholders Foundation
GlobeNewswire - Wed Aug 31, 9:15AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed in New York on behalf of certain purchasers of shares of Keryx Biopharmaceuticals (NASDAQ:KERX) over alleged Securities Laws Violations by Keryx Biopharmaceuticals. The lawsuit seeks to recover damages for certain NASDAQ:KERX investors.
KERX: 4.15 (+0.02)
KERX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Keryx Biopharmaceuticals, Inc. and a Lead Plaintiff Deadline of October 3, 2016
BusinessWire - Wed Aug 31, 9:09AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) securities February 25, 2016 and August 1, 2016.
KERX: 4.15 (+0.02)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline - October 3, 2016
ACCESSWIRE - Wed Aug 31, 9:07AM CDT
NEW YORK, NY / ACCESSWIRE / August 31, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District, Southern District of New York, on behalf of those who purchased shares of Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (NASDAQ: KERX) between February 25, 2016 and July 29, 2016 inclusive (the "Class Period".
KERX: 4.15 (+0.02)
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm
ACCESSWIRE - Tue Aug 30, 4:12PM CDT
IRVINE, CA / ACCESSWIRE / August 30, 2016 / Khang & Khang LLP (the "Firm" announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (NASDAQ: KERX). Investors who purchased or otherwise acquired shares between February 25, 2016 and August 1, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the October 3, 2016 lead plaintiff motion deadline.
KERX: 4.15 (+0.02)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Keryx Biopharmaceuticals, Inc.
GlobeNewswire - Tue Aug 30, 11:31AM CDT
Rigrodsky & Long, P.A.:
KERX: 4.15 (+0.02)
Technical Roundup on Biotech Stocks -- Keryx Biopharma, Inovio Pharma, Seattle Genetics, and Arrowhead Pharma
PR Newswire - Tue Aug 30, 7:15AM CDT
The Biotech arena includes companies that use biological processes to develop technological solutions, and manufacture products intended to improve the quality of life. Stocks under assessment on Stock-Callers.com today are: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Inovio Pharmaceuticals Inc. (NASDAQ: INO), Seattle Genetics Inc. (NASDAQ: SGEN), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up today and download for free the research reports for the stocks covered today at:
INO: 9.08 (-0.06), ARWR: 7.15 (+0.09), SGEN: 44.78 (-0.12), KERX: 4.15 (+0.02)
Weakness Seen in Keryx Biopharmaceuticals (KERX) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:38AM CDT
Keryx Biopharmaceuticals (KERX) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
ANIK: 47.89 (-0.05), KERX: 4.15 (+0.02)
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE - Mon Aug 29, 4:52AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Lundin Law PC (the "Firm" announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (NASDAQ: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the "Class Period". Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline.
KERX: 4.15 (+0.02)
KERYX SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Keryx Biopharmaceuticals Inc. - KERX
BusinessWire - Fri Aug 26, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 3, 2016 to file lead plaintiff applications in a securities class action lawsuit against Keryx Biopharmaceuticals Inc. (NasdaqCM: KERX), if they purchased the Company's securities between February 25, 2016, and August 1, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the Southern District of New York.
KERX: 4.15 (+0.02)
Keryx Biopharmaceuticals, Inc. Sued By Block & Leviton For Violations Of The Federal Securities Laws
PR Newswire - Fri Aug 26, 8:00PM CDT
Block & Leviton LLP (blockesq.com) announces that it has filed a class action lawsuit against Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company" (NASDAQ: KERX) and certain of its officers for violations of the federal securities laws.
KERX: 4.15 (+0.02)
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE - Fri Sep 02, 10:45PM CDT
LOS ANGELES, CA / ACCESSWIRE / September 2, 2016 / Lundin Law PC (the "Firm"
announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (NASDAQ: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the "Class Period". Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline. KERX: 4.15 (+0.02)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - KERX
ACCESSWIRE - Fri Sep 02, 7:00PM CDT
NEW YORK, NY / ACCESSWIRE / September 2, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company"
(NASDAQ: KERX) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-06233, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Keryx securities between February 25, 2016 and July 29, 2016 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act". KERX: 4.15 (+0.02)
Commit To Purchase Keryx Biopharmaceuticals At $3, Earn 26.7% Using Options
DividendChannel.com - Thu Sep 01, 10:47AM CDT
Investors considering a purchase of Keryx Biopharmaceuticals Inc. stock, but tentative about paying the going market price of $4.11/share, might benefit from considering selling puts among the alternative strategies at their disposal.
KERX: 4.15 (+0.02)
Keryx Biopharmaceuticals to Present at Two Upcoming Investor Healthcare Conferences
GlobeNewswire - Thu Sep 01, 7:30AM CDT
Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast management presentations at the following investor conferences:
KERX: 4.15 (+0.02)
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm
ACCESSWIRE - Wed Aug 31, 5:03PM CDT
IRVINE, CA / ACCESSWIRE / August 31, 2016 / Khang & Khang LLP (the "Firm"
announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (Nasdaq: KERX). Investors who purchased or otherwise acquired shares between February 25, 2016 and August 1, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the October 3, 2016 lead plaintiff motion deadline. KERX: 4.15 (+0.02)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. - KERX
GlobeNewswire - Wed Aug 31, 2:53PM CDT
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Keryx Biopharmaceuticals, Inc. securities (NASDAQ:KERX) from February 25, 2016 through August 1, 2016, both dates inclusive (the "Class Period"
. The lawsuit seeks to recover damages for Keryx Biopharmaceuticals investors under the federal securities laws. KERX: 4.15 (+0.02)
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Keryx Biopharmaceuticals, Inc.
Marketwire Canada - Wed Aug 31, 2:29PM CDT
OKLAHOMA CITY, OK--(Marketwired - Aug 31, 2016) - On August 26, 2016, a class action lawsuit was filed in the United States District Court for the District of Massachusetts against Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is September 2, 2013 through August 1, 2016.
KERX: 4.15 (+0.02)
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE - Wed Aug 31, 10:27AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the "Firm"
announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (Nasdaq: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the "Class Period". Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline. KERX: 4.15 (+0.02)
Lawsuit for Investors in shares of Keryx Biopharmaceuticals (NASDAQ:KERX) announced by Shareholders Foundation
GlobeNewswire - Wed Aug 31, 9:15AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed in New York on behalf of certain purchasers of shares of Keryx Biopharmaceuticals (NASDAQ:KERX) over alleged Securities Laws Violations by Keryx Biopharmaceuticals. The lawsuit seeks to recover damages for certain NASDAQ:KERX investors.
KERX: 4.15 (+0.02)
KERX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Keryx Biopharmaceuticals, Inc. and a Lead Plaintiff Deadline of October 3, 2016
BusinessWire - Wed Aug 31, 9:09AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) securities February 25, 2016 and August 1, 2016.
KERX: 4.15 (+0.02)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline - October 3, 2016
ACCESSWIRE - Wed Aug 31, 9:07AM CDT
NEW YORK, NY / ACCESSWIRE / August 31, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District, Southern District of New York, on behalf of those who purchased shares of Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company"
(NASDAQ: KERX) between February 25, 2016 and July 29, 2016 inclusive (the "Class Period". KERX: 4.15 (+0.02)
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm
ACCESSWIRE - Tue Aug 30, 4:12PM CDT
IRVINE, CA / ACCESSWIRE / August 30, 2016 / Khang & Khang LLP (the "Firm"
announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (NASDAQ: KERX). Investors who purchased or otherwise acquired shares between February 25, 2016 and August 1, 2016 inclusive (the "Class Period", are encouraged to contact the Firm prior to the October 3, 2016 lead plaintiff motion deadline. KERX: 4.15 (+0.02)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Keryx Biopharmaceuticals, Inc.
GlobeNewswire - Tue Aug 30, 11:31AM CDT
Rigrodsky & Long, P.A.:
KERX: 4.15 (+0.02)
Technical Roundup on Biotech Stocks -- Keryx Biopharma, Inovio Pharma, Seattle Genetics, and Arrowhead Pharma
PR Newswire - Tue Aug 30, 7:15AM CDT
The Biotech arena includes companies that use biological processes to develop technological solutions, and manufacture products intended to improve the quality of life. Stocks under assessment on Stock-Callers.com today are: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Inovio Pharmaceuticals Inc. (NASDAQ: INO), Seattle Genetics Inc. (NASDAQ: SGEN), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up today and download for free the research reports for the stocks covered today at:
INO: 9.08 (-0.06), ARWR: 7.15 (+0.09), SGEN: 44.78 (-0.12), KERX: 4.15 (+0.02)
Weakness Seen in Keryx Biopharmaceuticals (KERX) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:38AM CDT
Keryx Biopharmaceuticals (KERX) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
ANIK: 47.89 (-0.05), KERX: 4.15 (+0.02)
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE - Mon Aug 29, 4:52AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Lundin Law PC (the "Firm"
announces a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (NASDAQ: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the "Class Period". Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline. KERX: 4.15 (+0.02)
KERYX SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Keryx Biopharmaceuticals Inc. - KERX
BusinessWire - Fri Aug 26, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 3, 2016 to file lead plaintiff applications in a securities class action lawsuit against Keryx Biopharmaceuticals Inc. (NasdaqCM: KERX), if they purchased the Company's securities between February 25, 2016, and August 1, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the Southern District of New York. KERX: 4.15 (+0.02)
Keryx Biopharmaceuticals, Inc. Sued By Block & Leviton For Violations Of The Federal Securities Laws
PR Newswire - Fri Aug 26, 8:00PM CDT
Block & Leviton LLP (blockesq.com) announces that it has filed a class action lawsuit against Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company"
(NASDAQ: KERX) and certain of its officers for violations of the federal securities laws. KERX: 4.15 (+0.02)
